Floatz logo

Motesanib Diphosphate

Lymphoproliferative Syndrome

Jonsson Comprehensive Cancer CenterPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Lymphoproliferative Syndrome cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Baclofen
Alliance for Clinical Trials in Oncology
Phase 3BB
Amitriptyline
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Motesanib Diphosphate is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
46 / 100
View asset →
lung cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →